Business Wire

CA-CONVIVA

24.8.2022 16:03:10 CEST | Business Wire | Press release

Share
Conviva’s Breakthrough Streaming Analytics Innovation Recognized With Two ACM SIGCOMM Innovation Awards

Conviva , the leading global streaming analytics platform, has been recognized by the Association for Computing Machinery’s Special Interest Group on Data Communications (ACM SIGCOMM) with two prestigious innovation awards: the ACM SIGCOMM Test of Time Award and the SIGCOMM Networking Systems Award. Both awards honor the vision and impact of Conviva’s commitment to data and analytics technology innovation that began with the founding team of Hui Zhang, Aditya Ganjam, Jibin Zhan (Conviva) and Ion Stoica (Conviva, Databricks) defining standards that pushed the industry forward. This team’s work has continued to be foundational to enabling and continuously improving the quality and overall end-user experience that is industry standard in streaming media today. This same core technology has also proven applicable to virtually any industry where technology and business leaders have a business imperative to make the vast amount of their data available to their organizations in real time, and actionable across every aspect of their operations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220824005274/en/

2022 SIGCOMM Test of Time Award

The 2022 ACM SIGCOMM Test of Time Award honors Conviva’s founders for their 2011 paper detailing the direct connection between video quality and user engagement. The annual award recognizes papers published 10 to 12 years in the past that are deemed to offer data, perspective and predictions that still have significance today.

“What we didn’t predict was who would be the winners and losers of the streaming wars,” said Hui Zhang, Conviva Cofounder, Chief Scientist and Chairman of the Board. “What we did know ten years ago, and still holds true today, is that measuring quality and engagement in streaming is core to market growth and who comes out on top. Having this real-time information at their fingertips is mission-critical for publishers and brands to inform any actions to optimize their services and maximize their investment.”

The breakthrough technology that underscored the Test of Time award was documented in a paper, “Understanding the Impact of Video Quality on User Engagement” that was first presented at the 2011 ACM SIGCOMM conference. Its authors were Conviva founders Hui Zhang, Ion Stoica, Aditya Ganjam and Jibin Zhan, along with teammates Florin Dobrian, Asad Awan, Dilip Joseph and Vyas Sekar, an academic collaborator and now Professor of Carnegie Mellon University. The paper pioneered large-scale video measurements and documented an in-depth study conducted on how video quality affects user engagement, which has had a lasting impact on the optimization of streaming media.

The State of Streaming

While video streaming quality has significantly improved in the past 10 years, consumer expectations have also risen to new heights. Nothing short of high resolution and smooth playback all-the-time is acceptable. Detection and identifying root-cause of any barriers to an excellent experience is more challenging than ever due to the complexity of today’s streaming technology ecosystem. Diverse mobile-connected TV devices and associated video/app tech stacks, sophisticated cloud-based media preparation, content distribution, and advertising tech stacks all can contribute to more microscopic and subtle failure modes. More than a trillion-dollar market (ranging from media, entertainment, sports, education and fitness industries) is built on top of streaming, making it table stakes to ensure every media consumer has the best experience.

Each quarter, Conviva conducts an in-depth global review of streaming quality and adoption in a report entitled The State of Streaming.

2022 SIGCOMM Networking Systems Award

A separate SIGCOMM award committee also selected Conviva as the recipient of the 2022 SIGCOMM Networking Systems Award, recognizing the development of a networking system that has had a significant impact on the world of communications and computer networks. According to the committee, Conviva was recognized for “the sustained impact that Conviva has had, from the earliest days of translating published research to a successful real-world system, making a significant impact on real-world streaming systems and CDNs and then continuing to give back to the research community via data sharing and publications.”

“While I am very proud that Conviva has been recognized for its impact on the industry, our contribution to the research community is also very meaningful,” added Zhang. “I am thankful to all of our academic collaborators and talented undergrad and graduate interns from top research programs at CMU, Berkeley, Chicago, Purdue, and USC.”

The 2022 Test of Time winners were selected by an esteemed committee of technology experts that included Fadel Adib (MIT), Venkat Padmanabhan (Microsoft Research India, chair), Jennifer Rexford (Princeton) and Renata Teixeira (Netflix). The 2022 SIGCOMM Networking Systems Award was selected by a committee that included Vishal Misra, Anees Shaikh and Puneet Sharma.

About ACM SIGCOMM

The Association for Computing Machinery (ACM) is the world’s largest educational and scientific computing society, and SIGCOMM is ACM’s professional forum for the discussion of topics in the field of communications and computer networks, including technical design and engineering, regulation and operations, and the social implications of computer networking. The SIG's members are particularly interested in the systems engineering and architectural questions of communication.

About Conviva

Conviva helps streaming businesses act within seconds of observation to grow their business ahead of the competition. Conviva’s leading global streaming analytics platform provides comprehensive, continuous, census-level measurement through real-time, server side sessionization at scale. Using just a single sensor and a single pipeline, its 60+ patent platform enables marketers, advertisers, tech ops, engineering and customer care teams to acquire, engage, monetize and retain their audiences. Conviva is dedicated to supporting brands like DAZN, Disney+, Hulu, Paramount+, Peacock, Sky, Sling TV, TED and WarnerMedia as they unlock the incredible opportunity in streaming media. Today the Conviva platform processes nearly 3 trillion streaming data events daily, supporting more than 500 million unique viewers watching 200 billion streams per year across 4 billion applications streaming on devices. To learn more, visit www.conviva.com .

Link:

ClickThru

Social Media:

https://www.facebook.com/convivainc

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays1.9.2026 07:00:00 CEST | Press release

H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. "The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “As a pioneer in neurological diagnostics, Fujirebio remains committed to advancing patient care through innovative, fully automated testing solutions." These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions designed to inform clinical decision-making across the

Helical Fusion Named a Final Candidate for Japan’s METI Fusion Power Demonstration Program1.9.2026 04:00:00 CEST | Press release

Milestone-based government program supports multiple fusion approaches toward power demonstration and commercialization Helical Fusion Co., Ltd., a fusion energy company developing a Helical Stellarator toward commercially viable fusion power, has been named a final candidate for Japan’s Ministry of Economy, Trade and Industry (METI) program supporting the demonstration of fusion power generation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831991676/en/ Image of Helix HARUKA, Helical Fusion’s Integrated Demo Device(left), and Helix KANATA, Helical Fusion’s Fusion Pilot Plant(right) The program is designed to accelerate fusion power demonstration in the 2030s under Japan’s national energy and fusion strategies. It supports private-sector technology development across multiple fusion approaches, including tokamak, stellarator and laser fusion, with approximately JPY 60 billion in total government support anticipated ove

Strategic Combination of ITC Infotech and Happiest Minds Technologies to Create a Scaled, Future-Ready, AI-First Global Technology Services Enterprise with US$ 1 Billion Revenue by FY28[1]31.8.2026 23:35:00 CEST | Press release

ITC Infotech Board approves proposed acquisition of 22.1% promoter stake and a Scheme of Amalgamation of the two companies ITC Infotech (ITCI), a wholly owned subsidiary of ITC Limited and a leading global technology services player, today announced the proposed strategic combination with Happiest Minds Technologies Limited (Happiest Minds) to create a scaled, future-ready, AI-first global technology services enterprise. The ITCI Board approved a proposal to acquire 22.1% equity stake from the promoter of Happiest Minds in two tranches under a Share Purchase Agreement. The transaction would be funded through a Rights Issue by ITC Infotech. ITCI Board has also approved a proposed Scheme of Amalgamation of Happiest Minds with ITCI which will be effected after the share acquisition. Pursuant to the scheme, the shares of ITCI will be listed on the stock exchanges. The proposed transaction has also been endorsed by the Board of Directors of ITC Limited. This strategic combination will syner

Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule31.8.2026 21:07:00 CEST | Press release

Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations. Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.” “Our main focus is to provide great service to and being a rock-solid partner for our cu

BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 21:00:00 CEST | Press release

Agreement advances patient access and strengthens BeOne's long-term commitment to U.S. innovation and manufacturing BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional res

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye